Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate

Capricor Therapeutics Inc CAPR has partnered with Nippon Shinyaku Co Ltd for the exclusive commercialization and distribution in the U.S of Capricor's CAP-1002 for Duchenne muscular dystrophy (DMD).

• Capricor's proprietary cell therapy, CAP-1002, comprises human allogeneic cardiosphere-derived cells.
• HOPE-Duchenne and HOPE-2, the Phase 1 and Phase 2 clinical trials of CAP-1002, showed statistically significant improvements in upper limb and/or cardiac function in the treatment groups. 
• HOPE-3, the Phase 3 clinical trial that this partnership will support, will commence shortly and is expected to be the pivotal trial for CAP-1002 in DMD.
• Capricor will receive an upfront payment of $30 million with potential additional milestone payments of up to $705 million.
• Capricor will receive a double-digit percentage of revenue based on product sales.
• Price Action: CAPR shares are up 8.19% at $3.06 during the market session on the last check Tuesday.